阿尔兹海默氏症 z-bo 2020-10-20 404

　　Recently, a new study from the Royal Institute of Technology in Sweden pointed out that a new artificial protein can successfully inhibit dementia in mice carrying the human Alzheimer's gene. Related research may be related to the development of treatment methods. Treating the disease offers hope.

　　In this article, researchers have developed a binding protein that can target amyloid β protein polypeptide. Amyloid beta protein is directly involved in the development of Alzheimer's disease. When combined with this binding protein, the researchers found that experimental mice carrying the human Alzheimer's gene did not suffer from disease-related memory or cognitive deficits.

　　"The binding protein can also inhibit the formation of amyloid plaques in the brains of laboratory mice. Researcher Lindbergh pointed out that he was very pleased with the significantly reduced levels of amyloid beta protein in the mouse brain. This new type of binding protein can mimic the function of antibodies, but is much smaller than that of antibodies. Researchers have developed a new type of binding protein that can have a variety of different pathogenicities using an engineered protein called an affinity body. The protein binds tightly and specifically. In this study, the researchers used a new protein to specifically bind to the amyloid peptide protein that causes Alzheimer's disease. The mice treated with Affibody engineered protein behaved like healthy animals. Researchers say the relevant findings provide concrete ideas for the development of new treatments for Alzheimer's disease.

　　At the same time, researchers may be able to develop useful drugs within 10 years to help patients tolerate dementia and other senile diseases. Nowadays, Alzheimer's disease is a common dementia. There are many drugs to treat this symptom, but current drugs cannot effectively target the mechanism that causes the disease, so they are the effective source. There is no cure.

　　According to data from the Alzheimer’s Association, there are currently 35 million people with Alzheimer’s disease. Researchers estimate that this number will triple by 2050. As the disease progresses, the patient's brain function will cause the death of brain cells. In this research, Researcher Steinney said that he has developed a new type of protein that can inhibit Alzheimer's disease. Therefore, I want to pass future research. On this basis, develop truly effective treatments to help control the outbreak of diseases.